Options on Drugs: Industry Exposure and Option Anomalies
“Furthermore, the biotechnology bubble of the early 2000s inhibits common option risk factors from fully capturing the returns of pharmaceutical options.”
AssetEquitiesoptions
StrategyOptions strategiesvolatility risk premium
Missing from abstract: benchmark, out-of-sample test, costs, multiple testing, universe
Institutional-grade audit of this strategy.
£5 — Request the audit- Audit of the paper claims accounting for costs, luck, crises, originality, geography, etc.
- Reproduction code integratable into Bloomberg, IBKR, etc.
- Bias-free datasets for backtesting included
- Delivered in 2 working days
The paper's neighbourhoodOptions trading strategies by year
The family is counted across the whole universe. Asset, method and authors are counted inside the family.
| Similar papers | citation | same method | same asset | same authors | |
|---|---|---|---|---|---|
| Default Risk and Option Returns by Vasquez and Xiao | 2024 | ||||
| Option Return Predictability by Zhan et al. | 2021 | ||||
| Very Noisy Option Prices and Inference Regarding the Volatility Risk Premium by Duarte et al. | 2022 | ||||
| The Common Source of Option Return Anomalies by Gerchik | 2026 | ||||
| Option Factor Momentum by Käfer et al. | 2023 |